No­var­tis’ $2B can­cer drug spurs ‘ground­break­ing’ PhI­II da­ta for prostate can­cer

Con­tin­u­ing a streak of up­beat an­nounce­ments on its ra­di­oli­gand port­fo­lio, No­var­tis says that their Phase III study of 177Lu-PS­MA-617 hit both co-pri­ma­ry end­points on over­all …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER